The Role of Tumor Mutational Burden in Lung Cancer

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.

Related Videos

September 2, 2015

Relapsed/Refractory Setting

Dixie-Lee Esseltine, MD and George Mulligan, PhD discuss the challenges in the current standards of care of patients with multiple myeloma in the relapse setting.

October 10, 2016

Immunotherapy’s Role in Treating Hormone Receptor–Positive Diseases

Dr Thomas Bachelot discusses the potential for incorporating immunotherapy into the treatment of patients with hormone receptor–positive diseases but notes that the current data are weak, and further studies are needed to get a better sense of the viability of this treatment option.